{
  "bio": [
    "Kim Hyun-tae is CEO of South Korean biotechnology company Voronoi.",
    "Voronoi's two most promising cancer drug candidates are VRN10 and VRN11. Both started Phase 1 clinical trials in the first quarter of 2025.",
    "Voronoi was founded by Kim's younger brother, Hyun-seok, in 2015. The older Kim took over the company in 2016 and listed it on Korea's Kosdaq in 2022.",
    "Previously, Kim did stints as head of asset management at eBest Investment & Securities, Hanwha Investment & Securities and KB Securities."
  ],
  "about": []
}